FDA approve boceprevir (Victrelis) for HCV
1 August 2011. Related: Hepatitis coinfection.
Hepatitis coinfection
FDA approve telaprevir (Incivek) to treat hepatitis C
1 August 2011. Related: Hepatitis coinfection.
FDA supplemental information about using boceprevir and telaprevir
1 August 2011. Related: Hepatitis coinfection.
The hepatitis C treatment pipeline
14 July 2011. Related: Pipeline report, Hepatitis coinfection.
First results from telaprevir in HIV/HCV coinfection
1 April 2011. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.
Hepatitis B drugs in development
1 July 2010. Related: Pipeline report, Hepatitis coinfection.
Hepatitis C treatment pipeline
1 July 2010. Related: Pipeline report, Hepatitis coinfection.
Route of HCV transmission in HIV-positive gay men is unlikely to be from semen
1 June 2010. Related: Conference reports, Hepatitis coinfection.
Hepatitis studies: IL28B genetics, HCV survival, FibroScan in acute HCV, MSM reinfection and responses to transplantation
1 June 2010. Related: Conference reports, Hepatitis coinfection.
The HCV pipeline efficacy and side effect of compounds in Phase 3 studies
20 February 2010. Related: Conference reports, Hepatitis coinfection.
HBV resistance to lamivudine at undetectable and low levels of viremia
22 August 2009. Related: Conference reports, Hepatitis coinfection, Drug resistance.
HIV and hepatitis coinfection guidelines (2009): online for comment
3 June 2009. Related: Guidelines, Hepatitis coinfection, BHIVA news.
Use of fibroscan as non-invasive alternative to liver biopsy in HCV/HIV coinfection
12 June 2008. Related: Conference reports, Hepatitis coinfection.
UK cohort reports sexual HCV reinfection in at least 5% HIV-positive gay men following sustained response to treatment
1 April 2008. Related: Conference reports, Hepatitis coinfection.
MELD score predictive of pre-transplant mortality in HCV coinfected patients
1 April 2008. Related: Conference reports, Hepatitis coinfection.
Does abacavir decrease SVR rates with HCV treatment?
1 April 2008. Related: Conference reports, Hepatitis coinfection.
No effect of interferon maintenance therapy on fibrosis progression in non-responders
1 April 2008. Related: Conference reports, Hepatitis coinfection.
Comparative study of pegylated interferon formulations in HCV monotherapy
1 February 2008. Related: Hepatitis coinfection.
Risk of antibody negative HCV infection in four US HIV cohorts: risk linked to IDU, elevated ALT and low CD4 count
2 October 2007. Related: Hepatitis coinfection.
HBV or HCV coinfection produced higher risk from treatment interruptions: drug holidays and hepatitis dont mix
3 September 2007. Related: Conference reports, Hepatitis coinfection.
BMS issue Dear Doctor letter about risk of entecavir in HIV/HBV coinfection
3 September 2007. Related: Hepatitis coinfection.
Low rates of HCV treatment among eligible injection drug users
3 July 2007. Related: Conference reports, Hepatitis coinfection.
Effect of HCV and HIV on mortality among injecting drug users
3 July 2007. Related: Conference reports, Hepatitis coinfection.
HCV/HIV-co-infected IDUs are at increased risk of death from hepatitis-related death in the HAART era, compared with HCV-mono-IDUs
3 July 2007. Related: Conference reports, Hepatitis coinfection.
Scherings pegylated interferon approved for treating hepatitis C in HIV coinfected patients
3 July 2007. Related: Hepatitis coinfection.
Sexual transmission of HCV in Brighton reported in HIV positive and HIV negative MSM
4 April 2007. Related: Conference reports, Hepatitis coinfection.
Hepatitis B drug entecavir reported to have anti-HIV viral activity in three patients
4 April 2007. Related: Conference reports, Hepatitis coinfection.
Increased prevalence of cardiovascular disease among HIV-positive individuals coinfected with hepatitis C
5 February 2007. Related: Hepatitis coinfection.
Higher doses of ribavirin increases response rate to HCV treatment in coinfected patients: results from PRESCO study
6 December 2006. Related: Conference reports, Hepatitis coinfection.
NNRTI levels high in HCV co-Infected patients with cirrhosis
6 December 2006. Related: Conference reports, Hepatitis coinfection.
Nucleoside inhibitor MK-0608 mediates suppression of HCV replication for >30 days in chronically infected chimpanzees
7 October 2006. Related: Conference reports, Hepatitis coinfection.
Efficacy of treatment of acute hepatiitis C in patients with HIV infection
3 August 2006. Related: Hepatitis coinfection.
HIV/HCV coinfection: re-treating hepatitis C in people coinfected with HIV
13 April 2006. Related: Pipeline report, Hepatitis coinfection.
Sexual transmission of hepatitis C in HIV-positive men in the UK
25 March 2006. Related: Conference reports, Hepatitis coinfection.
One third of HIV/HCV coinfected patients with normal ALT have advanced fibrosis in Spanish cohort
16 March 2006. Related: Conference reports, Hepatitis coinfection.
Low HIV viral load linked to hepatitis B vaccination response
8 February 2006. Related: Hepatitis coinfection.
HPA releases HCV report without mentioning sexual transmission among HIV-positive gay men
8 February 2006. Related: Hepatitis coinfection.
Management of hepatitis C and B in HIV-coinfected individuals: an overview of studies presented at the 3rd IAS Conference
13 October 2005. Related: Conference reports, Hepatitis coinfection.
EMEA statement on use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection
13 September 2005. Related: Side effects, Hepatitis coinfection.
HIV/HCV coinfection part 1
14 August 2005. Related: Hepatitis coinfection.
Sexual transmission and response to treatment in acute HCV infection in HIV-positive gay men coinfected with HIV
15 June 2005. Related: Conference reports, Hepatitis coinfection.
UK guidelines for liver transplant in HIV-positive patients
15 May 2005. Related: Guidelines, Hepatitis coinfection.
Sexual HCV reinfection of HIV-positive gay man while receiving PEG-interferon plus ribavirin
15 May 2005. Related: Hepatitis coinfection.
First European recommendations for the treatment of patients co-infected with HIV and HBV/HCV
15 May 2005. Related: Hepatitis coinfection.
Entecavir is effective against 3TC-resistant hepatitis B
18 April 2005. Related: Conference reports, Hepatitis coinfection.
Tenofovir is non-inferior to adefovir for the treatment of hepatitis B in HBV-HIV co-infected patients
18 April 2005. Related: Conference reports, Hepatitis coinfection.
Pegasys approved for HIV/hepatitis C coinfection in Europe and US
18 April 2005. Related: Hepatitis coinfection.
Pegasys approved in Europea for the treatment of chronic hepatitis B
18 April 2005. Related: Hepatitis coinfection.
HCV coinfection linked to discontinuing ART due to toxicity
31 January 2005. Related: Conference reports, Hepatitis coinfection.
Updated UK guidelines for HIV and hepatitis coinfection (2005)
29 January 2005. Related: Guidelines, Hepatitis coinfection.
Interferon plus 3TC for people with HIV/HBV coinfection
29 January 2005. Related: Hepatitis coinfection.
BHIVA audit on management of HIV/Hepatitis coinfection
6 November 2004. Related: Conference reports, Hepatitis coinfection.
3TC resistance leads to hepatitis B flare
6 November 2004. Related: Hepatitis coinfection.
Sight changes reported with PEG-interferon
6 November 2004. Related: Hepatitis coinfection.
BMS submits marketing applications for entecavir to treat HBV in US and Europe
6 November 2004. Related: Hepatitis coinfection.
Responses to hepatitis vaccinations: an optimum window for protection?
6 September 2004. Related: Conference reports, Hepatitis coinfection.
HBV vaccine, CD4 count and increasing response with double-dose
6 September 2004. Related: Conference reports, Coinfections and complications, Hepatitis coinfection.
Response to Hepatitis A (HAV) vaccine determined by CD4 count
6 September 2004. Related: Conference reports, Hepatitis coinfection.
Chiron relaxes patent licences for hepatitis C
6 September 2004. Related: Hepatitis coinfection.
The 39th Annual Meeting of the European Association for the Study of the Liver (39th EASL)
2 June 2004. Related: Hepatitis coinfection.
Tenofovir blocks viral replication in HBV monoinfected and in HIV-HBV coinfected patients with lamivudine resistance
2 June 2004. Related: Hepatitis coinfection.
Compared to Caucasians, Africans have significantly higher rates of fibrosis and cirrhosis despite lower levels of HBV replication
2 June 2004. Related: Hepatitis coinfection.
Undetectable HIV viral load in HIV-HCV coinfected patients slows liver fibrosis progression rate
2 June 2004. Related: Hepatitis coinfection.
Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T
3 April 2004. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1
2 April 2004. Related: Conference reports, Hepatitis coinfection.